By 2030, it is anticipated that the Mexico infectious disease therapeutics market will reach a value of $2.58 Bn from $1.8 Bn in 2022, growing at a CAGR of 4.6% during 2022-2030. Infectious Disease Therapeutics in Mexico is dominated by a few domestic pharmaceutical companies such as Silanes Laboratories, BIRMEX and Liomont Laboratories. The Infectious Disease Therapeutics market in Mexico is segmented into different therapeutic areas and different diseases type. The major factors affecting the Mexico infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious diseases treatment in various areas of Mexico.
By 2030, it is anticipated that the Mexico infectious disease therapeutics market will reach a value of $2.58 Bn from $1.8 Bn in 2022, growing at a CAGR of 4.6% during 2022-2030.
Mexico is an upper middle-income, developing country located in North America with a North Pacific Ocean, Gulf of Mexico, and Caribbean Sea coastline. Mexico is a vast country with a complex healthcare system that differs by location.
The government has achieved tremendous progress in reducing the spread of infectious diseases, but some infectious diseases, particularly those associated with poverty, such as tuberculosis (TB), dengue fever, and Chagas disease, continue to pose obstacles. Mexico has an intermediate risk of infectious illnesses, according to the World Factbook. Mexico's government spends 6.2% of its GDP on healthcare.
Market Growth Drivers Analysis
Infectious disorders such as tuberculosis, HIV/AIDS, and dengue fever are prevalent in Mexico. As a result, there is a high demand for effective treatments and prevention techniques. Mexico has a large population, is geographically close to the US economy, and has a comparatively low labour cost. These aspects could boost Mexico's infectious disease therapeutics market.
Market Restraints
In Mexico, the infectious illness therapies industry is frequently dominated by other pharmaceutical corporations as well as alternative therapy modalities such as traditional medicine. Companies may find it challenging to obtain market share and generate significant commercial growth as a result of this. Mexico has a wide economic gap, a significant level of informality in the labour sector, and rising criminality. These factors may deter new entrants into the Mexico infectious disease therapeutics market.
Key Players
August 2022: Birmex and the Indian pharmaceutical business Cipla signed a Strategic Alliance and Technology Transfer Agreement today. Marcelo Ebrard Casaubon, Secretary of Foreign Relations, travelled to India with the goal of boosting the Mexican health system through the negotiation of technology transfer agreements to produce vaccines and medications in Mexico.
May 2021: The Liomont factory will supply Mexico and Argentina, in addition to the other Latin American nations with which AstraZeneca has contracts.
Several bodies in Mexico regulate and reimburse infectious illness medicines, including the Federal Commission for Protection against Health Risks (COFEPRIS) and the Mexican Social Security Institute (IMSS). In Mexico, the public health system, which comprises the IMSS and the Institute of Security and Social Services for State Workers (ISSSTE), has a considerable influence on the reimbursement process for infectious disease treatments.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Mode of Treatment (Revenue, USD Billion):
By Applications (Revenue, USD Billion):
By Disease Type (Revenue, USD Billion):
By Target Organism (Revenue, USD Billion):
By End User (Revenue, USD Billion):
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
By 2030, it is anticipated that the Mexico infectious disease therapeutics market will reach a value of $2.58 Bn from $1.8 Bn in 2022, growing at a CAGR of 4.6% during 2022-2030.
In Mexico, the regulation and reimbursement of infectious disease therapeutics are overseen by several entities, including the Federal Commission for Protection against Health Risks (COFEPRIS) and the Mexican Social Security Institute (IMSS).
Infectious Disease Therapeutics in Mexico is dominated by a few domestic pharmaceutical companies such as Silanes Laboratories, BIRMEX and Liomont Laboratories.